Dataset Information

Isolation and characterization of marine sponge-associated Streptomyces sp. NMF6 strain producing secondary metabolite(s) possessing antimicrobial, antioxidant, anticancer, and antiviral activities.

ABSTRACT:

Background

Actinomycetes associated with marine sponge represent a promising source of bioactive compounds. Herein, we report the isolation, identification, and bioactivity evaluation of Streptomyces sp. NMF6 associated with the marine sponge Diacarnus ardoukobae.

Results

Results showed that the strain belonged to the genus Streptomyces, and it was designated as Streptomyces sp. NMF6 with the GenBank accession number MW015111. Ethyl acetate (EtOAc) extract of the strain NMF6 demonstrated a promising antimicrobial activity against Staphylococcus aureus, Enterococcus faecalis, Vibrio damsela, and Candida albicans and a strong antioxidant activity, which were confirmed by DPPH, ferric-reducing power, and phosphomolybdenum assays; results are expressed as ascorbic acid equivalents. NMF6 extract also demonstrated cytotoxicity against breast cancer cell line (MCF-7), hepatocellular carcinoma cell line (Hep-G2), and human colon carcinoma cell line (HCT-116); the selectivity index values were < 2. The extract showed promising antiviral activity against HSV-1, CoxB4, and hepatitis A viruses at concentrations that were nontoxic to the host cells, with the selectivity index values being 13.25, 9.42, and 8.25, respectively. GC-MS analysis of the extract showed the presence of 20 compounds, with bis(2-ethylhexyl) phthalate being the major component (48%).

Conclusions

Our study indicates that the marine sponge-associated Streptomyces sp. NMF6 strain is a potential source of bioactive compounds that could be developed into therapeutic agents.

SUBMITTER: Fahmy NM

PROVIDER: S-EPMC8281025 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Staphylococcus epidermidis, the common inhabitant of human skin and mucosal surfaces has emerged as an important pathogen in patients receiving surgical implants and medical devices. Entering the body via surgical sites and colonizing the medical devices through formation of multi-layered biofilms it leads to refractory and persistent device-related infections (DRIs). Staphylococcal proportions within biofilms are more tolerant to antibiotics and immune responses, and thus are hard-to-treat. The consequent morbidity and mortality, and economic losses in health care systems has strongly necessitated the need for development of new anti-bacterial and anti-biofilm based therapeutics. In this study, we describe the biological activity of a marine sponge-derived Streptomyces sp. SBT348 extract in restraining staphylococcal growth and biofilm formation on polystyrene, glass, medically relevant titan metal and silicone surfaces. A bio-assay guided fractionation was performed to isolate the active compound (C3) from the crude SBT348 extract. Our results demonstrated that C3 effectively inhibits the growth (MIC: 31.25 µg/ml) and biofilm formation (sub-MIC range: 1.95-<31.25 µg/ml) of S. epidermidis RP62A in vitro. Chemical characterization of C3 by heat and enzyme treatments, and High-Resolution Fourier Transform Mass Spectrometry (HRMS) revealed its heat-stable and non-proteinaceous nature, and high molecular weight (1258. 3257 Da). Cytotoxicity profiling of C3 in vitro on mouse fibroblast (NIH/3T3) and macrophage (J774.1) cell lines, and in vivo on the greater wax moth larvae Galleria melonella revealed its non-toxic nature at the effective dose. Transcriptome analysis of C3 treated-S. epidermidis RP62A has further unmasked the negative effect of C3 on central metabolism (carbon, amino acid and protein, lipids, nucleotide and energy) suggesting its mode of action. Taken together, these findings suggest that C3 could be possibly used as antibacterial and antibiofilm coatings on medically-relevant surfaces and prevent the relapsing staphylococcal DRIs.